p53 and cancer therapy: a double-edged sword
Open Access
- 1 August 1999
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 104 (3) , 223-225
- https://doi.org/10.1172/jci7861
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.Genes & Development, 1994
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Apoptosis in cancer therapy: Crossing the thresholdCell, 1994
- p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genesNature, 1994
- p53, guardian of the genomeNature, 1992
- Induction of apoptosis in fibroblasts by c-myc proteinCell, 1992
- A genetic model for colorectal tumorigenesisCell, 1990